Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Disease analysis

Disease analysis


  • Sort by Price
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Market Spotlight: Venous Thromboembolism (VTE)

    $1,318.00

    This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

    May 13, 2022
    Find out more
  • Market Spotlight: Myelofibrosis (MF)

    $1,318.00

    Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.

    March 24, 2022
    Find out more
  • Market Spotlight: Ischemic Stroke

    $1,318.00

    This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

    May 12, 2022
    Find out more
  • Market Spotlight: Lysosomal Storage Disorders

    $1,318.00

    This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, probability of success, and clinical trials.

    April 28, 2022
    Find out more
  • Market Spotlight: Glioblastoma (GBM)

    $1,318.00

    This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    April 14, 2022
    Find out more
  • Market Spotlight: Thyroid Eye Disease (TED)

    $1,318.00

    Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.

    March 17, 2022
    Find out more
  • Market Spotlight: Dry Eye Disease

    $1,318.00

    This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    April 14, 2022
    Find out more
  • Digital Health: Diabetes Apps and Virtual Coaching

    $2,250.00

    Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications. Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized “virtual diabetes coaching” services.

    March 10, 2020
    Find out more
  • 2019 Post-ADA Report

    $2,995.00

    The American Diabetes Association (ADA) 79th Scientific Sessions was held in San Francisco, CA from 7–11 June 2019.

    July 22, 2019
    Find out more
  • Diabetes Management: Blood Glucose Monitoring Devices Market

    $4,750.00

    According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.

    December 19, 2019
    Find out more
  • Diabetes Management: Insulin Pumps Market (2019)

    $4,750.00

    This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

    September 30, 2019
    Find out more
  • Drug Delivery: Inhalation Devices

    $4,750.00

    This comprehensive market and medical technology report provides an overview of the inhalation-based devices used in the management of asthma and chronic obstructive pulmonary disease (COPD), and includes an in-depth, product-specific market analysis. Countries covered by this report comprise the US, the five major EU markets (France, Germany, Italy, Spain, and the UK), and Japan.

    October 7, 2019
    Find out more
  • Minimally Invasive Heart Valve Repair and Replacement Devices

    $4,750.00

    This comprehensive medical market and technology report provides an overview and in-depth market analysis of the transcatheter heart valve products used in the treatment of heart valve stenosis, regurgitation, and other valvular disorders.

    October 13, 2019
    Find out more
  • 2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

    $4,750.00

    The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for…

    October 18, 2019
    Find out more
  • Transcatheter Embolization and Occlusion Devices

    $4,750.00

    This comprehensive medical market and technology report provides an overview and in-depth market analysis of the global market for transcatheter embolization and occlusion devices.

    February 25, 2020
    Find out more
  • Neurointervention: Mechanical Thrombectomy Devices Market

    $4,750.00

    This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and arteriovenous malformation (AVM) embolization systems.

    October 30, 2020
    Find out more
  • 2020 Post-ESMO Report

    $4,750.00

    The Annual European Society for Medical Oncology (ESMO) 2020 Congress was held virtually from September 19 to September 21, 2020 due to the COVID-19 pandemic.

    October 5, 2020
    Find out more
  • Diabetes Management: Insulin Pumps Market (2020)

    $4,750.00

    This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

    December 30, 2020
    Find out more
  • Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

    $4,750.00

    This report provides a detailed presentation of diabetes and blood glucose monitoring devices, including standard fingerstick-based blood glucose meters (BGMs) and new sensor-based continuous glucose monitoring systems (CGMs) that attach to the body and monitor blood glucose 24 hours a day

    March 31, 2021
    Find out more
  • Biomedtracker Meddevice Tracker Early 2022 Outlook Report

    $4,750.00

    Biomedtracker Meddevice Tracker Early 2022 Outlook Report

    February 8, 2022
    Find out more
  • Disease Analysis: Asthma

    Read More

    Since its launch as the first fixed-dose combination (FDC) of an inhaled corticosteroid (ICS) and a long-acting beta 2 agonist (LABA), GlaxoSmithKline’s Advair has become a well-established gold-standard therapy in asthma. However, generic competition in Europe, and more recently in the US, marks the end of this successful history.

    March 21, 2022
    Find out more
  • Disease Analysis: Chronic Obstructive Pulmonary Disease (COPD)

    Read More

    The “ABCD” GOLD treatment guidelines focus on exacerbation risk and patient-reported outcomes to determine pharmacological treatment strategies, independent of spirometric value. Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist Spiriva in the treatment of more severe COPD.

    March 21, 2022
    Find out more
  • Disease Analysis: Cystic Fibrosis

    Read More

    Cystic fibrosis, caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein, is a rare and life-limiting genetic disorder that is characterized by thick, sticky mucus and pulmonary complications.

    April 7, 2022
    Find out more
  • Disease Analysis: Chronic Heart Failure

    Read More

    Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, or structural disorders of the myocardium or valves.

    March 31, 2021
    Find out more
  • Stroke Disease Coverage

    Ischemic Stroke Market and Forecast Analysis 2024

    Read More

    Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to either a neurological deficit persisting beyond 24 hours or death.

    January 7, 2019
    Find out more
  • Pulmonary hypertension

    Disease Analysis: Pulmonary Hypertension

    Read More

    Pulmonary hypertension (PH) is a life-threatening and often fatal disease characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to a progressive increase in pulmonary vascular resistance (PVR) and, ultimately, the development of right ventricular (RV) dysfunction. Cornerstone histopathological features of the PH vasculopathy include intimal thickening, concentric hypertrophy, and perivascular fibrosis of distal pulmonary arterioles.

    May 20, 2022
    Find out more
  • Disease Analysis: Head and Neck Cancer

    Read More

    Head and neck cancers (HNCs) are defined as any cancer that begins in cells of the oral cavity, pharynx, nose, sinuses, or salivary glands. These cancers are grouped together due to historical similarities in etiology, disease presentation, and manifestation. The vast majority of these cases (90%), collectively referred to as head and neck squamous cell carcinomas (HNSCCs), appear in squamous epithelial cells lining the mucous membranes of these regions. The exception to this is salivary gland cancer, which can appear in any of the salivary glands’ diverse cell types.

    February 11, 2022
    Find out more
  • Disease Analysis: HER2+ Breast Cancer

    Read More

    Amplification of the HER2/neu oncogene and related genetic elements on chromosome 17 increases HER2 expression and accelerates tumorigenesis. The natural disease progression meant that, historically, women with breast cancer who overexpressed HER2 were found to have significantly shorter disease-free survival and overall survival compared with women without HER2 amplification; however, the introduction of trastuzumab in 1998 drastically changed patient outcomes, to the point where HER2+ breast cancer patients now have the longest median survival of all breast cancer subtypes. HER2 is overexpressed in approximately 20% of breast cancers.

    May 20, 2022
    Find out more
  • Disease Analysis: HR+/HER2- Breast Cancer

    Read More

    Hormone receptor-positive (HR+) is the most common breast cancer subtype, with approximately 70% of breast cancers presenting with overexpression of estrogen receptors, progesterone receptors, or both (De Placido and Pronzato, 2015). Overexpression of the hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

    May 20, 2022
    Find out more
  • Disease Analysis: Triple-Negative Breast Cancer

    Read More

    Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.

    May 20, 2022
    Find out more
  • Disease Analysis: Ovarian Cancer

    Read More

    Ovarian cancer is defined as a group of tumors that originate in the ovaries. Most ovarian cancers are epithelial carcinomas which begin in the tissue surrounding the ovary. Other less common types of ovarian tumors include primary peritoneal, fallopian tube, and malignant germ cell tumors. Ovarian cancer is the fourth most common cancer among women, and is the leading cause of gynecological cancer-related death in women.

    May 19, 2022
    Find out more
  • Colorectal Cancer

    Disease Analysis: Colorectal Cancer

    Read More

    Colorectal (or bowel) cancer refers to carcinomas arising in the epithelium of the large intestine at any point between the cecal valve and the anus. CRC typically develops through the proliferation of mucosal epithelial cells of the gastrointestinal (GI) wall, eventually forming a polyp or adenoma. As with many other cancers of the GI tract, the vast majority (>95%) are adenocarcinomas.

    March 1, 2022
    Find out more
  • Disease Analysis: Gastric Cancer

    Read More

    Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach. The vast majority (95%) of these cancers are adenocarcinomas, and can be further grouped by anatomic origin. The clearest etiological distinction exists between adenocarcinomas of the gastric cardia (the anterior edge of the stomach surrounding the entry point of the esophagus), and those arising in the other anatomical subsites of the stomach – the fundus, body, pylorus, and the antrum. In most cases, gastric adenocarcinomas will begin in the muscularis mucosae and submucosa, then invading deeper lamina of the gastric wall.

    May 18, 2022
    Find out more
  • Hepatocellular carcinoma (HCC)

    Disease Analysis: Hepatocellular Carcinoma (HCC)

    Read More

    Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.

    May 19, 2022
    Find out more
  • Disease Analysis: Melanoma

    Read More

    Melanoma accounts for just 1% of all skin cancer cases, but is responsible for the majority of skin cancer-related deaths. Melanoma occurs when melanocytes – pigment-producing cells of the skin that are intercalated in the basal cell layer – become malignant. Although surgical excision is a potentially curative option for many melanoma patients, the disease can disseminate rapidly. Currently, only 27.3% of patients diagnosed with distant metastatic melanoma survive for five years, compared to about 99.0% of those with localized disease. Although 83% of patients present with localized disease, approximately one quarter to one third of these patients will eventually experience disease recurrence.

    February 25, 2022
    Find out more
  • Disease Analysis: Multiple Myeloma

    Read More

    Multiple myeloma (MM) is a hematological malignancy characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. The disease represents approximately 1% of all cancers, and 10% of hematological cancers. The hallmarks of MM are high levels of monoclonal (M-) protein, high levels of clonal plasma cells in the bone marrow, and organ damage.

    May 25, 2022
    Find out more
  • Disease Analysis: Prostate Cancer

    Read More

    Prostate cancer occurs when malignant cells originate in the prostate gland. The vast majority of prostate cancers are adenocarcinomas, but other less common types include sarcomas, small cell carcinomas, neuroendocrine tumors, and transitional cell carcinomas. Some prostate cancers can grow and spread quickly, but many are relatively indolent. Because of this, depending on patient age and other co-morbidities, some prostate cancer patients may not receive active treatment for the disease during their lifetime.

    March 2, 2022
    Find out more
  • FOLLICULAR LYMPHOMA

    Disease Analysis: NHL: Follicular Lymphoma

    Read More

    Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL) specifically originating from centrocyte and centroblast B cells and usually beginning in the lymph nodes. The disease is among the most common forms of NHL alongside diffuse large B-cell lymphoma (DLBCL), accounting for approximately 35% of all NHLs.

    March 10, 2022
    Find out more
  • Disease Analysis: Acute Myeloid Leukemia (AML)

    Read More

    AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow, which may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell. “Acute” means that the leukemia may progress rapidly – AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including the lymph nodes, spleen, central nervous system, and testicles.

    April 11, 2022
    Find out more
  • chronic lymphocytic leukemia

    Chronic Lymphocytic Leukemia (CLL)

    Read More

    The CLL treatment paradigm has changed significantly over the past five years, with targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors displacing chemotherapy-based treatments for most patients who have CLL.

    March 21, 2022
    Find out more
  • Disease Analysis: Chronic Myeloid Leukemia (CML)

    Read More

    Chronic myeloid leukemia (CML) is defined as a cancer of the blood in which a mutation in myeloid hematopoietic stem cells causes the overproduction of immature and dysfunctional white blood cells (myeloblasts, also known as blasts), preventing the normal production and function of healthy white blood cells, red blood cells, and platelets.

    February 25, 2022
    Find out more
  • HIV Disease Coverage Forecast and Market Analysis to 2027

    Read More

    The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages.

    June 28, 2019
    Find out more
  • Dengue vaccines

    Disease Analysis: Dengue Vaccines

    Read More

    Dengue virus is a member of the Flaviviridae family, which are also known for causing other diseases including yellow fever, West Nile virus, and tick-borne encephalitis. There are four serologically distinct dengue viruses (DENV-1, DENV-2, DENV-3, and DENV-4), meaning that recovery from infection provides immunity against a specific serotype, but there is little to no cross-immunity towards other serotypes. As a result, a person can be infected multiple times in their lifetime, with subsequent infections being more likely to be severe due to a phenomenon called antibody-dependent enhancement of disease.

    April 12, 2022
    Find out more
  • Disease Analysis: Meningococcal Vaccines

    Read More

    Meningococcal meningitis is caused by the bacteria Neisseria meningitidis, which causes a serious infection to the lining surrounding the brain and spinal cord. In all, 12 known serogroups of Neisseria meningitidis have been identified, six of which (A, B, C, W, X, and Y) can cause epidemics. The Centers for Disease Control and Prevention (CDC) has reported around 1 in 10 people are asymptomatic carriers of the bacteria.

    January 10, 2022
    Find out more
  • Disease Analysis: Pneumococcal Vaccines

    Read More

    Streptococcus pneumoniae (S. pneumoniae) is a bacterium that can cause multiple types of pneumococcal disease, including bloodstream infections (sepsis), pneumonia, meningitis, and other milder diseases such as sinusitis and otitis media. The severity of pneumococcal disease is characterized as invasive or non-invasive, with invasive pneumococcal disease being more severe as the bacterium can be isolated from ordinarily sterile sites (eg blood or cerebrospinal fluid), and requires hospital treatment.

    April 22, 2022
    Find out more
Page 3 of 4
Page 3 of 41234
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top